Since the measurement of CRP shows some advantages, such as high stability and low-cost dosage, it is proposed that CRP could be used alone as an inflammatory biomarker in MDD, independently of IL-6 (Carboni, 2013; Galvão-Coelho et al., 2020). The gene discussed is CRP; the disease is major depressive disorder.